Get started
Work

GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders

Year: 2025
Type: article
Abstract: Glucagon-like peptide-1 receptor (GLP-1R) agonists have revolutionized the therapeutic landscape of diabetes and obesity, yet their therapeutic potential extends significantly further. Research using human data and animal models indicates that systemically administered GLP-1R agonists access receptors in the periphery and in the brain. The latter site of action underlies the apparent efficacy of GLP-1R agonists to treat pathological consummatory behaviors that lead not only to obesity but also to binge-type eating disorders, alcohol use disorder, and other substance use disorders. This article provides an overview of basic science research, human clinical data, and real-world observations relevant to these topics and presented in a symposium at the 2025 Annual Meeting of the Society for Neuroscience.
DOI: 10.1523/jneurosci.1375-25.2025
Institutions: University of Florida Health, University of Florida, University of Pennsylvania, National Institutes of Health, National Institute on Drug Abuse, Eli Lilly (United States), Florida State University
Language: English
Open Access status: hybrid
Awards: G112997953, G1609483281, G176239059, G3020371426, G359523008, G4524472400, G5292266901, G5410588365, G5434050373, G5539864174, G863660190, G8647303224
OpenAlex ID: W4416197060
FWCI: 2.837
Cites: 100
Cited by: 8
Related to: